XLRS: Phase I/II data

Top-line data from 8 patients with XLRS in an open-label, U.S. Phase I/II trial showed that low- and mid-dose

Read the full 195 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE